<br>        Inclusion Criteria:<br><br>          1. Signed informed consent.<br><br>          2. Negative pregnancy test before first dose.<br><br>          3. Female and male participants willing to use acceptable and highly effective methods of<br>             birth control.<br><br>          4. The following criteria must be fulfilled by participants:<br><br>               1. Require daily analgesia for their pain,<br><br>               2. Diagnosed with active cancer,<br><br>               3. Receiving daily opioid treatment at doses not higher than 90 mg oral morphine or<br>                  its equivalent (World Health Organization Step II and Step III analgesics) for an<br>                  appropriate length of time,<br><br>               4. Participants must be dissatisfied with their current pain treatment,<br><br>               5. Participants must be suffering from cancer-related but not cancer therapy-related<br>                  chronic pain for a period of 4 weeks or more prior to enrollment.<br><br>          5. Eastern Cooperation Oncology Group (ECOG) score 2 or below.<br><br>          6. Average pain intensity over the last 24 hours of 5 or more calculated from the pain<br>             assessments recorded during the last 3 days prior to randomization.<br><br>          7. Compliance with the use of the electronic diary defined as at least 3 out of 4 of the<br>             24 hour Numerical Rating Scale entries available during the last 4 days prior to and<br>             including the day of allocation to treatment.<br><br>        Exclusion Criteria:<br><br>          1. Evidence of ongoing alcohol and or drug abuse and/or a history of alcohol and/or drug<br>             abuse within the last 2 years.<br><br>          2. A clinically significant disease other than cancer which in the investigator's opinion<br>             may affect efficacy or safety assessments e.g., significant unstable cardiac,<br>             vascular, pulmonary, gastrointestinal, endocrine, neurological, infectious disease,<br>             psychiatric (resulting in disorientation, memory impairment or inability to report<br>             accurately) or metabolic disorders.<br><br>          3. Any gastrointestinal disorder that could affect the absorption and/or elimination of<br>             Investigational Medicinal Product.<br><br>          4. Any planned major surgery during the trial.<br><br>          5. Known to or suspected of not being able to comply with the trial protocol and the use<br>             of Investigational Medicinal Product.<br><br>          6. History of seizure disorder and/or epilepsy or any condition associated with a<br>             significant risk of seizure or epilepsy.<br><br>          7. Known history and/or presence of cerebral tumor or cerebral metastases.<br><br>          8. Moderate to severe hepatic impairment corresponding to Child-Pugh classification B and<br>             C. Impaired hepatic cellular integrity indicated by aspartate transaminase or alanine<br>             transaminase greater than 3 times the upper limit of normal at the Enrollment Visit.<br><br>          9. Inadequate baseline bone marrow reserve with a white blood cell count below 2000/µL, a<br>             platelet count 100 000/µL or less, and a hemoglobin level below 8 g/dL at the<br>             Enrollment Visit.<br><br>         10. Impaired renal function. Creatinine clearance less than 60 mL per minute(as per<br>             amendment 45 mL per minute) at the Enrollment Visit (calculated from the<br>             Cockcroft-Gault formula).<br><br>         11. Forbidden concomitant medications<br><br>         12. Uncontrolled hypertension<br><br>         13. Clinically relevant history of hypersensitivity, allergy or contraindications to<br>             opioid medication or any of the excipients of morphine sulfate (Prolonged Released or<br>             Immediate Release), or cebranopadol film-coated tablets.<br><br>         14. Chronic hepatitis B or C, or human immunodeficiency virus (HIV) known by history, or<br>             presence of active hepatitis B or C within the 3 months before the Enrollment Visit.<br><br>         15. History of torsade de pointes and/or presence of risk factors for torsade de pointes<br>             (e.g., heart failure, hypokalemia, or bradycardia).<br><br>         16. Marked prolongation of corrected QT interval (Fridericia) (greater than 450<br>             milliseconds) at the Enrollment Visit.<br><br>         17. Employees of the sponsor, investigator, or trial site or family members of the<br>             employees, sponsor, or investigator.<br><br>         18. Concurrent participation in another trial or planning to be enrolled in another<br>             clinical trial (i.e., administration of experimental treatment in another clinical<br>             trial) during the course of this trial.<br><br>         19. Previous participation in this or other trials with cebranopadol with the following<br>             exceptions:<br><br>               -  Participants who failed enrollment in this trial only because of exclusion<br>                  criterion 10, and who may now be eligible can be re-enrolled.<br><br>               -  Participants who failed enrollment due to technical failure of equipment (e.g.,<br>                  ECG machine and e-diary device).<br><br>         20. Participant has received an experimental drug or used an experimental medical device<br>             within 30 days before the planned start of treatment.<br><br>         21. Currently not receiving opioid treatment for cancer-related pain at the enrollment<br>             visit (i.e., opioid naïve).<br>